Submission of Revised results for the quarter December 31, 2025.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Novelix Pharmaceuticals has submitted revised unaudited standalone results for the quarter ended 31 December 2025, correcting a typographical error in the auditor's limited review report. Total income for Q3 FY26 stood at Rs 4,840.27 lakhs, up sharply from Rs 530.09 lakhs in the same quarter last year. Net profit after tax was Rs 100.44 lakhs versus Rs 14.79 lakhs in Q3 FY25. For the nine months ended December 2025, total income was Rs 10,714.52 lakhs and net profit was Rs 164.46 lakhs, compared to a small loss of Rs 7.65 lakhs in the year-ago period. Basic EPS for the quarter was Rs 0.58 versus Rs 0.15 a year ago. The auditor (CVS Balachandra Rao & Co.) issued an unqualified limited review report.
Strong year-on-year revenue and profit growth signals a turnaround in the business after the company's name and activity change to pharmaceuticals. For shareholders, this is a positive earnings update, though investors should note the revision was administrative and the stock remains a small-cap, so liquidity and disclosure quality warrant caution.